Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Conditions

Carcinoma, Non-Small-Cell Lung 48Breast Neoplasms 48Lung Neoplasms 34Ovarian Neoplasms 33Fallopian Tube Neoplasms 22Carcinoma, Ovarian Epithelial 21Adenocarcinoma of Lung 16Unspecified Adult Solid Tumor, Protocol Specific 13Brenner Tumor 11Adenocarcinoma, Bronchiolo-Alveolar 11Head and Neck Neoplasms 10Breast Neoplasms, Male 10Neoplasm Metastasis 9Uterine Cervical Neoplasms 7Triple Negative Breast Neoplasms 7Squamous Cell Carcinoma of Head and Neck 7Neoplasms 7Esophageal Neoplasms 7Endometrial Neoplasms 7Adenocarcinoma Of Esophagus 6Urinary Bladder Neoplasms 5Oropharyngeal Neoplasms 5Melanoma 5Precursor Cell Lymphoblastic Leukemia-Lymphoma 4Peritoneal Neoplasms 4Mouth Neoplasms 4Lymphoma, Non-Hodgkin 4Lymphoma, Mantle-Cell 4Lymphoma, Large-Cell, Immunoblastic 4Lymphoma, Large B-Cell, Diffuse 4

Interventions

X-Rays 1Taxes 1Specimen Handling 1Platinum 1Paclitaxel 1Etoposide 1Cisplatin 1Carboplatin 1Biopsy 11,2-diaminocyclohexaneplatinum II citrate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NIH × Advanced NUT Carcinoma × Paclitaxel × Clear all
NCT05019716 2026-05-13

Testing the Safety and Efficacy of the Addition of a New Anti-cancer Drug, ZEN003694, to Chemotherapy Treatment (Cisplatin and Etoposide or Carboplatin and Paclitaxel) for Adult and Pediatric Patients (12-17 Years) With NUT Carcinoma

National Cancer Institute (NCI)

Phase 1/2 Recruiting
36 enrolled

Advanced NUT Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡